Division of Pediatric Gastroenterology and Nutrition, Safra Children's Hospital, Tel-Hashomer, Israel.
Pediatr Pulmonol. 2010 Jun;45(6):536-40. doi: 10.1002/ppul.21138.
Probiotics reduce intestinal inflammation in, and Lactobacillus GG (LGG) reduces pulmonary exacerbation rate cystic fibrosis (CF) patients. We intended to determine the effect of a mixed probiotic preparation on pulmonary exacerbations and inflammatory characteristics of the sputum in CF patients.
A prospective pilot study of 10 CF patients with mild-moderate lung disease and Pseudomonas aeruginosa colonization, treated with probiotics for 6 months. Pulmonary function tests (PFT's), sputum cultures with semi-quantitative bacterial analysis, and sputum neutrophil count and interleukin-8 (IL-8) levels were compared to pre-treatment and post-treatment values. The rate of pulmonary exacerbations was compared to 2 years prior to the study.
The exacerbation rate was significantly reduced in comparison to the previous 2 years and to 6 months post-treatment (P = 0.002). PFT's have not changed at the end of treatment and during 6 months post-treatment. No change in sputum bacteria, neutrophil count, and IL-8 levels was observed.
Probiotics reduce pulmonary exacerbations rate in patients with CF. Probiotics may have a preventive potential for pulmonary deterioration in CF patients.
益生菌可减轻囊性纤维化（CF）患者的肠道炎症，而鼠李糖乳杆菌 GG（LGG）可降低 CF 患者的肺部恶化率。我们旨在确定混合益生菌制剂对 CF 患者肺部恶化和痰液炎症特征的影响。
对 10 名患有轻度至中度肺部疾病且定植铜绿假单胞菌的 CF 患者进行前瞻性试点研究，这些患者接受益生菌治疗 6 个月。比较肺功能测试（PFT）、痰液培养的半定量细菌分析、痰液中性粒细胞计数和白细胞介素-8（IL-8）水平与治疗前和治疗后的数值。将肺部恶化率与研究前 2 年进行比较。
与前 2 年和治疗后 6 个月相比，恶化率显著降低（P=0.002）。治疗结束时和治疗后 6 个月，PFT 没有变化。痰液细菌、中性粒细胞计数和 IL-8 水平没有变化。
益生菌可降低 CF 患者的肺部恶化率。益生菌可能对 CF 患者的肺部恶化具有预防潜力。
